Treatment
Ianalumab clinical trials
We’re tracking 6 recruiting studies that include Ianalumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07039422RecruitingPhase 2
Ianalumab re-treatment for ITP or wAIHA
This trial tests a re-treatment with ianalumab for people with ITP or warm-antibody autoimmune hemolytic anemia who previously benefited from the drug in an earlier Novartis study but then had their condition return after at least 2 years. It aims to see if a second course can help again.
Buenos AiresAges 18–100 - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Fayetteville, ArkansasAges 18 years+ - NCT06711887RecruitingPhase 3
Long-term extension study of ianalumab for lupus nephritis
This study is a follow-up for people with lupus nephritis who already completed a 144-week treatment course with ianalumab in an earlier study. It tests whether continuing or stopping the drug is safe and effective over the long term.
Orchard Park, New YorkAges 18–100 - NCT06470048RecruitingPhase 2
Testing Ianalumab for Diffuse Cutaneous Systemic Sclerosis
This trial tests a new drug called ianalumab for people with diffuse cutaneous systemic sclerosis (a type of scleroderma affecting the skin and internal organs). It aims to see if the drug can help control the disease activity and reduce skin thickening.
Mesa, ArizonaAges 18–70 - NCT06133972RecruitingPhase 3
Long-term safety of ianalumab for lupus (extension study)
This extension study tests the long-term safety of ianalumab for people with systemic lupus erythematosus. If you completed a prior SIRIUS-SLE study and your doctor thinks you'd benefit, you may continue treatment for up to 60 more weeks.
Anniston, AlabamaAges 12–100 - NCT07621809RecruitingPhase 3
Ianalumab versus placebo for Sjögren's disease with high symptom burden
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
Peoria, ArizonaAges 18 years+
What Ianalumab is being studied for
Conditions with recruiting Ianalumab studies.
Common questions
- Are there clinical trials studying Ianalumab?
- Yes. Clin2 currently lists 6 recruiting studies that include Ianalumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ianalumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ianalumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ianalumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.